FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956178192> ?p ?o ?g. }

• W2956178192 endingPage "764" @default.
• W2956178192 startingPage "761" @default.
• W2956178192 abstract "Despite widespread use of bendamustine and rituximab (BR) as frontline therapy for advanced-stage follicular lymphoma (FL), little is known about the risk of early progression or incidence of histological transformation. We performed a retrospective analysis of a population-based cohort of 296 patients with advanced-stage FL treated with frontline BR and maintenance rituximab. As previously demonstrated, outcomes with this regimen are excellent, with 2-year event-free survival estimated at 85% (95% confidence interval [95% CI], 80-89) and 2-year overall survival 92% (95% CI, 88-95). Progression of disease within 24 months (POD24) occurred in 13% of patients and was associated with a significantly inferior outcome with 2-year overall survival of 38% (95% CI, 20-55). The only significant risk factor for POD24 at baseline was elevated lactate dehydrogenase (P < .001). Importantly, the majority of POD24 patients (76%) had transformed disease. Compared with a historical cohort treated with rituximab, cyclophosphamide, vincristine, and prednisone, event-free survival has improved and the risk of POD24 has decreased, but a higher proportion of patients with POD24 harbor transformation. The overall incidence of transformation appears unchanged. The presence of occult or early transformation is the main driver of POD24 in FL patients treated with frontline BR. Identification of biomarkers and improved management strategies for transformation will be crucial to improving outcomes. Subjects: Brief Reports, Clinical Trials and Observations, Lymphoid Neoplasia Topics: bendamustine, follicular lymphoma, rituximab, biological markers, cyclophosphamide, lactate dehydrogenase, prednisone, vincristine, disease progression" @default.
• W2956178192 created "2019-07-23" @default.
• W2956178192 creator A5006888644 @default.
• W2956178192 creator A5008496216 @default.
• W2956178192 creator A5008961404 @default.
• W2956178192 creator A5017873196 @default.
• W2956178192 creator A5021133318 @default.
• W2956178192 creator A5022658681 @default.
• W2956178192 creator A5026641386 @default.
• W2956178192 creator A5033923876 @default.
• W2956178192 creator A5043505357 @default.
• W2956178192 creator A5045731423 @default.
• W2956178192 creator A5059082232 @default.
• W2956178192 creator A5060579616 @default.
• W2956178192 creator A5062342454 @default.
• W2956178192 creator A5075117420 @default.
• W2956178192 date "2019-07-12" @default.
• W2956178192 modified "2023-10-10" @default.
• W2956178192 title "Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma" @default.
• W2956178192 cites W1964744337 @default.
• W2956178192 cites W2085346499 @default.
• W2956178192 cites W2129200400 @default.
• W2956178192 cites W2150697204 @default.
• W2956178192 cites W2160093471 @default.
• W2956178192 cites W2169209759 @default.
• W2956178192 cites W2464635942 @default.
• W2956178192 cites W2505010070 @default.
• W2956178192 cites W2551589138 @default.
• W2956178192 cites W2561792671 @default.
• W2956178192 cites W2774937907 @default.
• W2956178192 cites W2789039113 @default.
• W2956178192 cites W2895212757 @default.
• W2956178192 cites W2906575149 @default.
• W2956178192 cites W2906951186 @default.
• W2956178192 cites W3041047318 @default.
• W2956178192 doi "https://doi.org/10.1182/blood.2019000258" @default.
• W2956178192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31300404" @default.
• W2956178192 hasPublicationYear "2019" @default.
• W2956178192 type Work @default.
• W2956178192 sameAs 2956178192 @default.
• W2956178192 citedByCount "65" @default.
• W2956178192 countsByYear W29561781922019 @default.
• W2956178192 countsByYear W29561781922020 @default.
• W2956178192 countsByYear W29561781922021 @default.
• W2956178192 countsByYear W29561781922022 @default.
• W2956178192 countsByYear W29561781922023 @default.
• W2956178192 crossrefType "journal-article" @default.
• W2956178192 hasAuthorship W2956178192A5006888644 @default.
• W2956178192 hasAuthorship W2956178192A5008496216 @default.
• W2956178192 hasAuthorship W2956178192A5008961404 @default.
• W2956178192 hasAuthorship W2956178192A5017873196 @default.
• W2956178192 hasAuthorship W2956178192A5021133318 @default.
• W2956178192 hasAuthorship W2956178192A5022658681 @default.
• W2956178192 hasAuthorship W2956178192A5026641386 @default.
• W2956178192 hasAuthorship W2956178192A5033923876 @default.
• W2956178192 hasAuthorship W2956178192A5043505357 @default.
• W2956178192 hasAuthorship W2956178192A5045731423 @default.
• W2956178192 hasAuthorship W2956178192A5059082232 @default.
• W2956178192 hasAuthorship W2956178192A5060579616 @default.
• W2956178192 hasAuthorship W2956178192A5062342454 @default.
• W2956178192 hasAuthorship W2956178192A5075117420 @default.
• W2956178192 hasBestOaLocation W29561781921 @default.
• W2956178192 hasConcept C126322002 @default.
• W2956178192 hasConcept C143998085 @default.
• W2956178192 hasConcept C203014093 @default.
• W2956178192 hasConcept C207103383 @default.
• W2956178192 hasConcept C2776694085 @default.
• W2956178192 hasConcept C2776755627 @default.
• W2956178192 hasConcept C2777058707 @default.
• W2956178192 hasConcept C2778720950 @default.
• W2956178192 hasConcept C2779338263 @default.
• W2956178192 hasConcept C2779429289 @default.
• W2956178192 hasConcept C2780653079 @default.
• W2956178192 hasConcept C2781442060 @default.
• W2956178192 hasConcept C2908647359 @default.
• W2956178192 hasConcept C44249647 @default.
• W2956178192 hasConcept C71924100 @default.
• W2956178192 hasConcept C99454951 @default.
• W2956178192 hasConceptScore W2956178192C126322002 @default.
• W2956178192 hasConceptScore W2956178192C143998085 @default.
• W2956178192 hasConceptScore W2956178192C203014093 @default.
• W2956178192 hasConceptScore W2956178192C207103383 @default.
• W2956178192 hasConceptScore W2956178192C2776694085 @default.
• W2956178192 hasConceptScore W2956178192C2776755627 @default.
• W2956178192 hasConceptScore W2956178192C2777058707 @default.
• W2956178192 hasConceptScore W2956178192C2778720950 @default.
• W2956178192 hasConceptScore W2956178192C2779338263 @default.
• W2956178192 hasConceptScore W2956178192C2779429289 @default.
• W2956178192 hasConceptScore W2956178192C2780653079 @default.
• W2956178192 hasConceptScore W2956178192C2781442060 @default.
• W2956178192 hasConceptScore W2956178192C2908647359 @default.
• W2956178192 hasConceptScore W2956178192C44249647 @default.
• W2956178192 hasConceptScore W2956178192C71924100 @default.
• W2956178192 hasConceptScore W2956178192C99454951 @default.
• W2956178192 hasIssue "9" @default.
• W2956178192 hasLocation W29561781921 @default.
• W2956178192 hasOpenAccess W2956178192 @default.
• W2956178192 hasPrimaryLocation W29561781921 @default.

• next